FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair.
Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion cited by analysts.
Roche said it was still targeting an increase in full-year adjusted earnings per share at a high single-digit percentage.
(Reporting by Ludwig Burger, Editing by Rachel More)
